

**EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION
IN JAPAN FOR INSOMNIA TREATMENT SEP-190**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that it has submitted a Marketing Authorization Application (MAA) to the Japanese Ministry of Health, Labour and

[Notes to editors]

1. About SEP-190

Generic Name: eszopiclone

SEP-190 is a non-benzodiazepine type GABA_A agonist (non-benzodiazepine sedative hypnotic) that was originally discovered and developed by Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.). It is an S-enantiomer obtained